Fmr LLC Rallybio Corp Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Rallybio Corp stock. As of the latest transaction made, Fmr LLC holds 2,290,058 shares of RLYB stock, worth $2.27 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,290,058

Previous 2,279,618 0.46%

Holding current value

$2.27 Million

Previous $4.22 Million 27.25%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.34 - $2.98 $13,989 - $31,111	10,440 Added 0.46%	2,290,058 $3.07 Million
Q1 2024 May 13, 2024	SELL	$1.25 - $2.4 $319,941 - $614,287	-255,953 Reduced 10.09%	2,279,618 $4.22 Million
Q4 2023 Feb 13, 2024	SELL	$1.91 - $4.39 $1.36 Million - $3.12 Million	-710,716 Reduced 21.89%	2,535,571 $6.06 Million
Q3 2023 Nov 13, 2023	BUY	$3.37 - $6.16 $1,934 - $3,535	574 Added 0.02%	3,246,287 $10.9 Million
Q2 2023 Aug 11, 2023	BUY	$4.31 - $8.89 $1,973 - $4,071	458 Added 0.01%	3,245,713 $18.4 Million
Q1 2023 May 11, 2023	SELL	$4.37 - $8.75 $742 - $1,487	-170 Reduced 0.01%	3,245,255 $18.5 Million
Q4 2022 Feb 13, 2023	BUY	$4.67 - $14.86 $1.64 Million - $5.22 Million	351,577 Added 12.15%	3,245,425 $21.3 Million
Q3 2022 Nov 10, 2022	BUY	$7.54 - $14.56 $2,194 - $4,236	291 Added 0.01%	2,893,848 $41.9 Million
Q2 2022 Aug 12, 2022	SELL	$6.26 - $13.65 $6,034 - $13,158	-964 Reduced 0.03%	2,893,557 $21.8 Million
Q1 2022 May 13, 2022	BUY	$6.91 - $15.04 $23,134 - $50,353	3,348 Added 0.12%	2,894,521 $20.2 Million
Q3 2021 Nov 15, 2021	BUY	$10.83 - $23.4 $31.3 Million - $67.7 Million	2,891,173 New	2,891,173 $50.8 Million

Others Institutions Holding RLYB

# of Institutions

Shares Held

32.1M

Call Options Held

Put Options Held

View Full List

About Rallybio Corp

Ticker RLYB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,132,000
Market Cap $31.8M
Description
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...

More about RLYB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account